Astera Labs (ALAB) Stock Falls Again — But 15 Analysts Say Buy the Dip

TLDR

• ALAB dropped 7.2% to $104.41 on March 30, hitting an intraday low of $102.20 on well below-average trading volume
• The stock is now 60% below its 52-week high of $262.90 and trading under both its 50-day ($138.30) and 200-day ($162.90) moving averages
• Q4 revenue was up 91.8% year-over-year and EPS beat estimates by $0.07, with Q1 2026 guidance set at $0.53–$0.54 EPS
• Analysts remain bullish with a consensus “Moderate Buy” and an average price target of $202.22 — nearly double the current price
• Insiders sold around 384,292 shares worth $48.7 million in the last three months, though they still own 12.5% of the company

Astera Labs (ALAB) slid 7.2% on March 30, closing at $104.41 after touching an intraday low of $102.20. The stock had closed at $112.47 the session prior.

Astera Labs, Inc. Common Stock, ALAB

Volume was notably thin. Around 566,620 to 1.7 million shares changed hands depending on the session snapshot — well below the daily average of roughly 5.1–5.2 million shares. Light volume on a down day can sometimes reflect a lack of conviction rather than a wave of selling pressure.

The drop pushes ALAB deeper into a painful stretch. The stock now sits 60% below its 52-week high of $262.90, though it remains more than 120% above its 52-week low of $47.13.

Both moving averages are pointing the wrong way. The 50-day sits at $138.30 and the 200-day at $162.90 — well above Monday’s close — confirming the stock has been in a downtrend for some time.

Strong Fundamentals, Weak Chart

The fundamentals tell a different story. In Q4, Astera Labs posted revenue of $270.58 million, up 91.8% year-over-year and ahead of the $249.46 million analyst consensus. EPS came in at $0.58, beating estimates of $0.51 by $0.07. Net margin stood at 25.70% and return on equity was 16.12%.

For Q1 2026, the company guided EPS of $0.53 to $0.54. On a full-year basis, analysts expect $0.34 EPS on average.

Wall Street hasn’t given up. Of 23 analysts covering the stock, 15 have a Buy rating, six a Hold, and just one a Sell. The consensus stands at “Moderate Buy” or “Outperform” depending on the data provider. Average price targets range from $202 to $204 — implying upside of roughly 95–97% from current levels. Individual targets go as high as $250–$275.

Insiders Have Been Selling

That optimism from analysts doesn’t extend to the executive suite, at least not recently. Over the past three months, insiders sold around 384,292 shares worth approximately $48.7 million.

General Counsel Philip Mazzara sold 10,000 shares on March 2 at $117.47, reducing his stake by 7.24%. COO Sanjay Gajendra sold 94,971 shares in February at an average of $123.81, trimming his position by 5.84%.

Despite those sales, insiders collectively still own 12.5% of the company. Institutional investors hold about 60.5% of the float, and several have been adding to positions recently. Royal Bank of Canada grew its stake by 167.3% in Q1. AQR Capital Management boosted its position by 213.4%. Empowered Funds increased its holdings by 917.3%.

At a market cap of $16.79 billion and a P/E ratio of 80.39, the stock carries a growth premium. The beta of 1.75 reflects its tendency to move sharply in both directions.

As of the March 30 close, ALAB was trading at $104.01–$104.41, roughly 60% below its all-time high and well under every major analyst price target.

The post Astera Labs (ALAB) Stock Falls Again — But 15 Analysts Say Buy the Dip appeared first on CoinCentral.